Neurocrine Biosciences
NBIX
#1366
Rank
โ‚ฌ13.31 B
Marketcap
133,57ย โ‚ฌ
Share price
0.84%
Change (1 day)
11.84%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : โ‚ฌ1.08 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are โ‚ฌ1.08 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Neurocrine Biosciences - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚ฌ1.08 B17.65%
2023-12-31โ‚ฌ0.92 B49.67%
2022-12-31โ‚ฌ0.61 B-0.11%
2021-12-31โ‚ฌ0.61 B24.67%
2020-12-31โ‚ฌ0.49 B-17.17%
2019-12-31โ‚ฌ0.59 B33.36%
2018-12-31โ‚ฌ0.44 B20.64%
2017-12-31โ‚ฌ0.37 B677.76%
2016-12-31โ‚ฌ47.73 M3.7%
2015-12-31โ‚ฌ46.03 M63.06%
2014-12-31โ‚ฌ28.23 M13.78%
2013-12-31โ‚ฌ24.81 M-21.12%
2012-12-31โ‚ฌ31.45 M-47.82%
2011-12-31โ‚ฌ60.28 M-35.89%
2010-12-31โ‚ฌ94.03 M101.49%
2009-12-31โ‚ฌ46.66 M-19.86%
2008-12-31โ‚ฌ58.23 M-46.17%
2007-12-31โ‚ฌ0.10 B90.43%
2006-12-31โ‚ฌ56.81 M-27.65%
2005-12-31โ‚ฌ78.52 M-15.05%
2004-12-31โ‚ฌ92.43 M-28.97%
2003-12-31โ‚ฌ0.13 B221.7%
2002-12-31โ‚ฌ40.45 M-0.65%
2001-12-31โ‚ฌ40.71 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Repligen
RGEN
โ‚ฌ0.72 B-33.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
โ‚ฌ8.35 B 670.65%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
โ‚ฌ8.68 M-99.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
โ‚ฌ78.23 B 7,116.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
โ‚ฌ117.23 B 10,715.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚ฌ99.31 B 9,062.11%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
โ‚ฌ0.77 B-28.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
โ‚ฌ37.63 M-96.53%๐Ÿ‡บ๐Ÿ‡ธ USA